| Literature DB >> 35104666 |
Devon Campbell1, Monica Reyes1, Sare Betul Kaygusuz2, Saygın Abali3, Tulay Guran2, Abdullah Bereket2, Masayo Kagami4, Serap Turan2, Harald Jüppner5.
Abstract
Individuals affected by pseudohypoparathyroidism type 1A (PHP1A) display hyperphosphatemia and hypocalcemia despite elevated PTH levels, as well as features of Albright Hereditary Osteodystrophy (AHO). PHP1A is caused by variants involving the maternal GNAS exons 1-13 encoding the stimulatory G protein α-subunit (Gsα). MLPA and aCGH analysis led in a male PHP1A patient to identification of a de novo 1284-bp deletion involving GNAS exon 1. This novel variant overlaps with a previously identified 1438-bp deletion in another PHP1A patient (ref. Li et al. (2020) [13], patient 2) that extends from the exon 1 promoter into the up-stream intronic region. This latter deletion is associated with reduced methylation at GNAS exon A/B, i.e. the differentially methylated region (DMR) that is demethylated in most pseudohypoparathyroidism type 1B (PHP1B) patients. In contrast, genomic DNA from our patient revealed no evidence for an epigenetic GNAS defect as determined by MS-MLPA and pyrosequencing. These findings thus reduce the region, which, in addition to other nucleotide sequences telomeric of exon A/B, may undergo histone modifications or interacts with transcription factors and possibly as-yet unknown proteins that are required for establishing the maternal methylation imprints at this site. Taken together, nucleotide deletions or changes within an approximately 1300-bp region telomeric of exon A/B could be a cause of PHP1B variants with complete or incomplete loss-of-methylation at the exon A/B DMR. In addition, when investigating patients with suspected PHP1A, MLPA should be considered to search for structural abnormalities within this difficult to analyze genomic region comprising GNAS exon 1.Entities:
Keywords: Albright hereditary osteodystrophy; Calcium; Epigenetics; GNAS methylation; Gs-alpha; Gsα; Parathyroid hormone; Phosphate; Pseudohypoparathyroidism type Ia (PHP1A)
Mesh:
Substances:
Year: 2022 PMID: 35104666 PMCID: PMC9301885 DOI: 10.1016/j.bone.2022.116344
Source DB: PubMed Journal: Bone ISSN: 1873-2763 Impact factor: 4.626